التفاصيل البيبلوغرافية
| العنوان: |
Plasmatic renin-angiotensin system in normotensive and hypertensive patients hospitalized with COVID-19. |
| المؤلفون: |
Silva, Mauro G.1 (AUTHOR), Corradi, Gerardo R.1 (AUTHOR), Pérez Duhalde, Juan I.2 (AUTHOR), Nuñez, Myriam3 (AUTHOR), Cela, Eliana M.4 (AUTHOR), Gonzales Maglio, Daniel H.4 (AUTHOR), Brizzio, Ana2 (AUTHOR), Salazar, Martin R.2 (AUTHOR), Espeche, Walter G.2 (AUTHOR), Gironacci, Mariela M.1 (AUTHOR) mariela@qb.ffyb.uba.ar |
| المصدر: |
Biomedicine & Pharmacotherapy. Aug2022, Vol. 152, pN.PAG-N.PAG. 1p. |
| مصطلحات موضوعية: |
*COVID-19, *RENIN-angiotensin system, *HYPERTENSION, *SARS disease, *ANGIOTENSIN converting enzyme |
| مستخلص: |
Besides its counterbalancing role of the renin-angiotensin system (RAS), angiotensin-converting enzyme (ACE) 2 is the receptor for the type 2 coronavirus that causes severe acute respiratory syndrome, the etiological agent of COVID-19. COVID-19 is associated with increased plasmatic ACE2 levels, although conflicting results have been reported regarding angiotensin (Ang) II and Ang-(1−7) levels. We investigated plasmatic ACE2 protein levels and enzymatic activity and Ang II and Ang-(1−7) levels in normotensive and hypertensive patients hospitalized with COVID-19 compared to healthy subjects. Ang II and Ang-(1−7), and ACE2 activity and protein levels were measured in 93 adults (58 % (n = 54) normotensive and 42 % (n = 39) hypertensive) hospitalized with COVID-19. Healthy, normotensive (n = 33) and hypertensive (n = 7) outpatient adults comprised the control group. COVID-19 patients displayed higher ACE2 enzymatic activity and protein levels than healthy subjects. Within the COVID-19 group, ACE2 activity and protein levels were not different between normotensive and hypertensive-treated patients, not even between COVID-19 hypertensive patients under RAS blockade treatment and those treated with other antihypertensive medications. Ang II and Ang-(1−7) levels significantly decreased in COVID-19 patients. When COVID-19 patients under RAS blockade treatment were excluded from the analysis, ACE2 activity and protein levels remained higher and Ang II and Ang-(1−7) levels lower in COVID-19 patients compared to healthy people. Our results support the involvement of RAS in COVID-19, even when patients under RAS blockade treatment were excluded. The increased circulating ACE2 suggest higher ACE2 expression and shedding. [Display omitted] [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder